United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Main Management ETF Advisors LLC

Main Management ETF Advisors LLC reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 8.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,136 shares of the biotechnology company’s stock after selling 192 shares during the period. Main Management ETF Advisors LLC’s holdings in United Therapeutics were worth $754,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC raised its stake in shares of United Therapeutics by 0.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after purchasing an additional 39 shares during the last quarter. Wedmont Private Capital acquired a new stake in United Therapeutics during the 4th quarter valued at approximately $466,000. Park Avenue Securities LLC increased its stake in shares of United Therapeutics by 18.4% in the fourth quarter. Park Avenue Securities LLC now owns 2,614 shares of the biotechnology company’s stock worth $922,000 after acquiring an additional 407 shares during the period. Burney Co. grew its position in United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after purchasing an additional 12,705 shares during the period. Finally, USA Financial Formulas lifted its holdings in United Therapeutics by 856.0% in the fourth quarter. USA Financial Formulas now owns 870 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 779 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares of the company’s stock, valued at $2,703,424. This represents a 22.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Raymond Dwek sold 4,000 shares of United Therapeutics stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the sale, the director now directly owns 1,750 shares in the company, valued at approximately $497,962.50. The trade was a 69.57% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 65,500 shares of company stock valued at $20,765,280. 11.90% of the stock is owned by company insiders.

United Therapeutics Trading Down 2.7%

UTHR stock opened at $299.68 on Thursday. The company has a market cap of $13.52 billion, a price-to-earnings ratio of 13.16, a PEG ratio of 0.97 and a beta of 0.58. The firm has a 50-day moving average of $300.21 and a two-hundred day moving average of $341.23. United Therapeutics Co. has a 12 month low of $264.33 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same quarter in the previous year, the company posted $6.17 earnings per share. The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on UTHR. HC Wainwright reaffirmed a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. Bank of America upgraded United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price target for the company in a research note on Monday, April 21st. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research report on Thursday, May 1st. Finally, Morgan Stanley boosted their price objective on United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a research report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $392.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.